World’s First Minimally Invasive Non-blood Contacting
Cardiac Assist Device to Treat Acute Heart Failure.

With a lead investment from Wellcome Trust, CorInnova is developing a minimally invasive, non-blood contacting cardiac assist device for acute heart failure treatment.  The device is intended to initially treat the large and fast-growing short-term cardiac assist market (up to 7 days’ use). It will expand this market to an $8B addressable market by treating the 50% of patients who cannot use, or are unsuitable for, existing cardiac assist devices. The device is collapsible allowing it to be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat.